Medication precautions for venetoclax

Venetoclax (Venetoclax), as a new type of targeted drug, has shown significant efficacy in cancer treatment. However, as with other medications, there are certain precautions that need to be taken when using venetoclax to ensure patient safety and the effectiveness of the medication.

Before starting treatment with venetoclax, physicians should assess the patient's risk for developing tumor lysis syndrome (TLS). TLS is a serious complication that may occur when a large number of cancer cells are rapidly killed, releasing large amounts of uric acid, potassium and phosphorus into the blood. Preventive measures include pre-administering antihyperuricemic drugs to patients before administration and ensuring that patients drink adequate fluids. For patients at increased overall risk, stronger countermeasures such as intravenous hydration, frequent monitoring, or even hospitalization may need to be applied.

Venetoclax may cause neutropenia and increase the risk of infection. Therefore, during treatment, doctors should regularly monitor patients' blood cell counts, especially the number of neutrophils. If a significant decrease in neutrophils is found, medication dosage adjustments or other treatments may be needed.

Venetoclax is primarily metabolized by the liver's CYP3A enzyme. Therefore, it is prohibited to use it in combination with strong CYP3A inhibitors, as these drugs will significantly reduce the metabolism of venetoclax and increase its blood concentration, which may lead to toxic reactions. In addition, simultaneous use with CYP3Amoderate inhibitors, CYP3Amoderate inducers, P-gp inhibitors or P-gp substrates with small therapeutic index should also be avoided to avoid interference with the metabolism or transport of venetoclax.

Because venetoclax may be passed to the infant through breast milk and poses an unknown risk to the infant, nursing women should discontinue breastfeeding during treatment.

Venetoclax may cause damage to the fetus, so women of childbearing potential should use effective contraception during treatment. If you are pregnant or planning to become pregnant, you should talk to your doctor promptly to evaluate the risks and benefits.

Venetoclax should be used with extreme caution in patients with severe hepatic and renal impairment, and dosage adjustments may be required.

In addition to the above contraindications and precautions, patients should also be aware of and pay attention to the common side effects that venetoclax may cause, such as neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia, and fatigue. Although these side effects are usually not life-threatening, they may affect the patient's quality of life and the effectiveness of treatment. Therefore, patients should closely observe their body's reactions and promptly report any discomfort or abnormal symptoms to their doctor.

In order to maintain stable blood concentrations and optimal therapeutic effects, patients should try to take venetoclax at the same time every day. If you miss a dose of medicine and it is discovered within 8 hours of the regular medication time, you should take it as soon as possible; if it exceeds 8 hours, you do not need to take it again and you can just continue regular medication. If the patient vomits after taking the dose, there is no need to take an additional dose that day.

The dosage of venetoclax will vary based on the patient's condition, physical condition, and underlying medical conditions. For patients with chronic lymphocytic leukemia, venetoclax is started in 5-week increments, ultimately reaching a maintenance dose of 400 mg per day. For patients with acute myeloid leukemia, the dosage of venetoclax is gradually increased to 400mg per day. Patients must strictly follow the doctor's instructions when adjusting the dosage of medication.